Researchers hope to harness immune cells for better treatment of allergies, infections
Can't see this email? View it online
   
  August 9, 2017  
  Allergy  
  The latest Allergy news from News Medical  
 Researchers hope to harness immune cells for better treatment of allergies, infectionsResearchers hope to harness immune cells for better treatment of allergies, infections
 
By learning how a recently discovered immune cell works in the body, researchers hope to one day harness the cells to better treat allergies and infections, according to new Cornell University research.
 
 
 Anti-allergy medicines may be effective treatment for deadly blood clots in the legsAnti-allergy medicines may be effective treatment for deadly blood clots in the legs
 
Common anti-allergy medicines could prove to be an effective treatment for potentially fatal blood clots in the legs, according to new research by the University of Birmingham.
 
   UM SOM awarded $2.47 million grant to develop vaccine against Shigella, ETEC infectionsUM SOM awarded $2.47 million grant to develop vaccine against Shigella, ETEC infections
 
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
 
   InDevR gets NIAID support for verification, validation studies on new potency test for influenza virusesInDevR gets NIAID support for verification, validation studies on new potency test for influenza viruses
 
InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, announced support from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, for verification and validation studies on a new potency test for influenza viruses with pandemic potential.
 
   Protein that protects fetus during pregnancy could help treat atopic dermatitisProtein that protects fetus during pregnancy could help treat atopic dermatitis
 
A protein which protects the fetus during pregnancy, HLA-G1, shows high potential for treating atopic dermatitis and other related diseases.
 
 Tackling food allergies: is immunotherapy the answer?
 
Tackling food allergies: is immunotherapy the answer?Food allergies affect approximately 8% of school children in the United States and the United Kingdom. The highest prevalence of food allergies is in Australia affecting approximately 10% of young children. It is lower in the developing world.
 
 
 Local Anesthesia
 
Local AnesthesiaThe localized loss of sensation with resultant reduction in pain stimuli is the end result of local anesthesia. This mode of anesthesia is considered to be safer than general anesthesia, because it bypasses the systemic (i.e. body-wide) effects seen with general anesthesia, such as a loss of consciousness and hemodynamic alterations.
 
 
 Actinic Cheilitis - Symptoms and Causes
 
Actinic Cheilitis - Symptoms and CausesAC is the acronym for actinic cheilitis and is a condition where the lower lip becomes dry, rough, and thick with scales. It is mainly caused by the excessive exposing of the lips to the sun, and for this reason actinis cheilitis is also known as solar cheilitis.
 
 
 New online healthcare platform iDoc enables patients to book consultations with GPs anytime
 
New online healthcare platform iDoc enables patients to book consultations with GPs anytimeOnline digital healthcare provider iDoc, launches, with the aim of transforming the way patients access and interact with GPs and Paediatricians, nationally. Part of the Fidelity Health Group, iDoc offers patients the ability to have a GP appointment at a time and in a way, that suits them.
 
 
 FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomes
 
FDA approves fixed dose combination chemotherapy for subtypes of AML that have poor survival outcomesThe U.S. Food and Drug Administration (FDA) yesterday approved Vyxeos - a fixed dose combination chemotherapy for the treatment of adults with two types of acute myeloid leukemia (AML). The types of AML that would be treated with Vyxeos include newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of the chemotherapy drugs daunorubicin and cytarabine.
 
 
 Increase in reported cases of Cyclospora infections compared to last year, CDC reports
 
Increase in reported cases of Cyclospora infections compared to last year, CDC reportsThe Centers for Disease Control and Prevention (CDC) has released a Health Alert Network (HAN) Health Advisory on 7th August 2017, Monday, in order to alert the health care facilities and the public health department on the increase in the reported cases of cyclosporiasis.